{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,7,11]],"date-time":"2024-07-11T06:34:04Z","timestamp":1720679644575},"reference-count":51,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2014,3,1]],"date-time":"2014-03-01T00:00:00Z","timestamp":1393632000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","europeanneuropsychopharmacology.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Neuropsychopharmacology"],"published-print":{"date-parts":[[2014,3]]},"DOI":"10.1016\/j.euroneuro.2013.11.009","type":"journal-article","created":{"date-parts":[[2013,12,16]],"date-time":"2013-12-16T23:16:46Z","timestamp":1387235806000},"page":"425-436","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["A novel analog of olanzapine linked to sarcosinyl moiety (PGW5) demonstrates high efficacy and good safety profile in mouse models of schizophrenia"],"prefix":"10.1016","volume":"24","author":[{"given":"Irit","family":"Gil-Ad","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Moshe","family":"Portnoy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Igor","family":"Tarasenko","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miri","family":"Bidder","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria","family":"Kramer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michal","family":"Taler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abraham","family":"Weizman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.euroneuro.2013.11.009_bib1","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1177\/070674370304801107","article-title":"From chlorpromazine to clozapine\u2014antipsychotic adverse effects and the clinician's dilemma","volume":"48","author":"Abidi","year":"2003","journal-title":"Can. J. Psychiatry"},{"key":"10.1016\/j.euroneuro.2013.11.009_bib2","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1038\/sj.mp.4001637","article-title":"BDNF in schizophrenia, depression and corresponding animal models","volume":"10","author":"Angelucci","year":"2005","journal-title":"Mol. Psychiatry"},{"key":"10.1016\/j.euroneuro.2013.11.009_bib3","doi-asserted-by":"crossref","first-page":"8394","DOI":"10.1523\/JNEUROSCI.18-20-08394.1998","article-title":"Multiple limbic regions mediate the disruption of prepulse inhibition produced in rats by the noncompetitive NMDA antagonist dizocilpine","volume":"18","author":"Bakshi","year":"1998","journal-title":"J. Neurosci."},{"key":"10.1016\/j.euroneuro.2013.11.009_bib4","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.pharmthera.2012.01.006","article-title":"Brain derived neurotrophic factor: a novel neurotrophin involved in psychiatric and neurological disorders","volume":"134","author":"Balaratnasingam","year":"2012","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.euroneuro.2013.11.009_bib5","doi-asserted-by":"crossref","first-page":"e61","DOI":"10.1038\/tp.2011.64","article-title":"Intracerebral adult stem cells transplantation increases brain-derived neurotrophic factor levels and protects against phencyclidine-induced social deficit in mice","volume":"1","author":"Barzilay","year":"2011","journal-title":"Transl. Psychiatry"},{"key":"10.1016\/j.euroneuro.2013.11.009_bib6","article-title":"Mesenchymal stem cells protect from sub-chronic phencyclidine insult in vivo and counteract changes in astrocyte gene expression in vitro","author":"Barzilay","year":"2012","journal-title":"Eur. Neuropsychopharmacol"},{"key":"10.1016\/j.euroneuro.2013.11.009_bib7","doi-asserted-by":"crossref","first-page":"1888","DOI":"10.1038\/sj.npp.1301312","article-title":"Abnormal glutamate receptor expression in the medial temporal lobe in schizophrenia and mood disorders","volume":"32","author":"Beneyto","year":"2007","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.euroneuro.2013.11.009_bib8","doi-asserted-by":"crossref","first-page":"2","DOI":"10.3389\/neuro.08.002.2009","article-title":"Effects of subchronic phencyclidine (PCP) treatment on social behaviors, and operant discrimination and reversal learning in C57BL\/6J mice","volume":"3","author":"Brigman","year":"2009","journal-title":"Front. Behav. Neurosci."},{"key":"10.1016\/j.euroneuro.2013.11.009_bib9","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/0893-133X(94)00129-N","article-title":"Radioreceptor binding profile of the atypical antipsychotic olanzapine","volume":"14","author":"Bymaster","year":"1996","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.euroneuro.2013.11.009_bib10","doi-asserted-by":"crossref","first-page":"12","DOI":"10.2174\/1874467211003010012","article-title":"Brain-derived neurotrophic factor: a dynamic gatekeeper of neural plasticity","volume":"3","author":"Cowansage","year":"2010","journal-title":"Curr. Mol. Pharmacol."},{"key":"10.1016\/j.euroneuro.2013.11.009_bib11","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1007\/s10571-006-9062-8","article-title":"Glutamate and schizophrenia: beyond the dopamine hypothesis","volume":"26","author":"Coyle","year":"2006","journal-title":"Cell Mol. Neurobiol."},{"key":"10.1016\/j.euroneuro.2013.11.009_bib12","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1176\/ps.49.2.196","article-title":"Compliance with medication regimens for mental and physical disorders","volume":"49","author":"Cramer","year":"1998","journal-title":"Psychiatr. Serv."},{"key":"10.1016\/j.euroneuro.2013.11.009_bib13","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/S0165-6147(02)02017-5","article-title":"Assessing antidepressant activity in rodents: recent developments and future needs","volume":"23","author":"Cryan","year":"2002","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.euroneuro.2013.11.009_bib14","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1176\/appi.ajp.2011.11010052","article-title":"Cortical deficits of glutamic acid decarboxylase 67 expression in schizophrenia: clinical, protein, and cell type-specific features","volume":"168","author":"Curley","year":"2011","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.euroneuro.2013.11.009_bib15","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1097\/00002826-200101000-00008","article-title":"A revised excitotoxic hypothesis of schizophrenia: therapeutic implications","volume":"24","author":"Deutsch","year":"2001","journal-title":"Clin. Neuropharmacol."},{"key":"10.1016\/j.euroneuro.2013.11.009_bib16","first-page":"17","article-title":"Regulation of intermittent oscillatory activity of pyramidal cell neurons by GABA inhibitory interneurons is impaired in schizophrenia: rationale for pharmacotherapeutic GABAergic interventions","volume":"47","author":"Deutsch","year":"2010","journal-title":"Isr. J. Psychiatry Relat. Sci."},{"key":"10.1016\/j.euroneuro.2013.11.009_bib17","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jpsychires.2011.09.022","article-title":"The role of BDNF in the pathophysiology and treatment of schizophrenia","volume":"46","author":"Favalli","year":"2012","journal-title":"J Psychiatr. Res."},{"key":"10.1016\/j.euroneuro.2013.11.009_bib18","doi-asserted-by":"crossref","first-page":"e1168","DOI":"10.4088\/JCP.12m07642","article-title":"Bl-1020, a new gamma-aminobutyric acid-enhanced antipsychotic: results of 6-week, randomized, double-blind, controlled, efficacy and safety study","volume":"73","author":"Geffen","year":"2012","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.euroneuro.2013.11.009_bib19","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1007\/s00213-004-2032-2","article-title":"A six-month, placebo-controlled trial of d-cycloserine co-administered with conventional antipsychotics in schizophrenia patients","volume":"179","author":"Goff","year":"2005","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.euroneuro.2013.11.009_bib20","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1001\/archpsyc.57.11.1061","article-title":"Decrease in reelin and glutamic acid decarboxylase67 (GAD67) expression in schizophrenia and bipolar disorder: a postmortem brain study","volume":"57","author":"Guidotti","year":"2000","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.euroneuro.2013.11.009_bib21","doi-asserted-by":"crossref","first-page":"2110","DOI":"10.1038\/npp.2010.87","article-title":"Evidence for abnormal forward trafficking of AMPA receptors in frontal cortex of elderly patients with schizophrenia","volume":"35","author":"Hammond","year":"2010","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.euroneuro.2013.11.009_bib22","doi-asserted-by":"crossref","first-page":"498","DOI":"10.7326\/0003-4819-157-7-201210020-00525","article-title":"Antipsychotics in adults with schizophrenia: comparative effectiveness of first-generation versus second-generation medications: a systematic review and meta-analysis","volume":"157","author":"Hartling","year":"2012","journal-title":"Annu. Intern. Med."},{"key":"10.1016\/j.euroneuro.2013.11.009_bib23","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1038\/nrd3893","article-title":"Glycine transporters as novel therapeutic targets in schizophrenia, alcohol dependence and pain","volume":"12","author":"Harvey","year":"2013","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.euroneuro.2013.11.009_bib24","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1523\/JNEUROSCI.4035-04.2005","article-title":"Relationship of brain-derived neurotrophic factor and its receptor TrkB to altered inhibitory prefrontal circuitry in schizophrenia","volume":"25","author":"Hashimoto","year":"2005","journal-title":"J. Neurosci."},{"key":"10.1016\/j.euroneuro.2013.11.009_bib25","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/S0028-3908(01)00043-0","article-title":"Pharmacological assessment of the role of the glycine transporter GlyT-1 in mediating high-affinity glycine uptake by rat cerebral cortex and cerebellum synaptosomes","volume":"41","author":"Herdon","year":"2001","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.euroneuro.2013.11.009_bib26","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1016\/j.pnpbp.2003.09.007","article-title":"Glutamatergic neurotransmission modulation and the mechanisms of antipsychotic atypicality","volume":"27","author":"Heresco-Levy","year":"2003","journal-title":"Prog. Neuropsychopharmacol. Biol. Psychiatry"},{"key":"10.1016\/j.euroneuro.2013.11.009_bib27","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1016\/j.biopsych.2004.12.037","article-title":"d-serine efficacy as add-on pharmacotherapy to risperidone and olanzapine for treatment-refractory schizophrenia","volume":"57","author":"Heresco-Levy","year":"2005","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.euroneuro.2013.11.009_bib28","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1146\/annurev.ne.17.030194.000335","article-title":"Cloned glutamate receptors","volume":"17","author":"Hollmann","year":"1994","journal-title":"Annu. Rev. Neurosci."},{"issue":"984\u2013997","key":"10.1016\/j.euroneuro.2013.11.009_bib29","article-title":"Glutamate as a therapeutic target in psychiatric disorders","volume":"9","author":"Javitt","year":"2004","journal-title":"Mol. Psychiatry"},{"key":"10.1016\/j.euroneuro.2013.11.009_bib30","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1007\/s00702-003-0826-8","article-title":"GAD(67): the link between the GABA-deficit hypothesis and the dopaminergic- and glutamatergic-theories of psychosis","volume":"110","author":"Kalkman","year":"2003","journal-title":"J. Neural Transm."},{"key":"10.1016\/j.euroneuro.2013.11.009_bib31","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1176\/ajp.156.2.286","article-title":"Clinical and theoretical implications of 5-HT2 and D2 receptor occupancy of clozapine, risperidone, and olanzapine in schizophrenia","volume":"156","author":"Kapur","year":"1999","journal-title":"Am. J. Psychiatry"},{"issue":"Suppl. 1","key":"10.1016\/j.euroneuro.2013.11.009_bib32","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/S0306-4530(02)00115-4","article-title":"Cognitive effects and antipsychotic treatment","volume":"28","author":"Kasper","year":"2003","journal-title":"Psychoneuroendocrinology"},{"key":"10.1016\/j.euroneuro.2013.11.009_bib33","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1017\/S1092852900010403","article-title":"Beyond monoamines: glutamatergic function in mood disorders","volume":"10","author":"Kugaya","year":"2005","journal-title":"CNS Spectr."},{"key":"10.1016\/j.euroneuro.2013.11.009_bib34","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1017\/S1461145709990939","article-title":"A randomized, double-blind, placebo-controlled comparison study of sarcosine (N-methylglycine) and d-serine add-on treatment for schizophrenia","volume":"13","author":"Lane","year":"2010","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"10.1016\/j.euroneuro.2013.11.009_bib35","doi-asserted-by":"crossref","first-page":"771","DOI":"10.2174\/156802606777057599","article-title":"Progress towards validating the NMDA receptor hypofunction hypothesis of schizophrenia","volume":"6","author":"Lindsley","year":"2006","journal-title":"Curr. Top. Med. Chem."},{"key":"10.1016\/j.euroneuro.2013.11.009_bib36","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1111\/j.1601-183X.2004.00071.x","article-title":"Automated apparatus for quantitation of social approach behaviors in mice","volume":"3","author":"Nadler","year":"2004","journal-title":"Genes Brain Behav."},{"key":"10.1016\/j.euroneuro.2013.11.009_bib37","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1038\/nrn3379","article-title":"Neurotrophin regulation of neural circuit development and function","volume":"14","author":"Park","year":"2013","journal-title":"Nat. Rev. Neurosci."},{"key":"10.1016\/j.euroneuro.2013.11.009_bib38","unstructured":"Poels, Kegeles, Kantrowitz, Slifstein, Javitt, Lieberman, bi-Dargham and Girgis, Imaging glutamate in schizophrenia: review of findings and implications for drug discovery, Mol. Psychiatry, in press"},{"key":"10.1016\/j.euroneuro.2013.11.009_bib39","first-page":"327","article-title":"Behavioral despair in mice: a primary screening test for antidepressants","volume":"229","author":"Porsolt","year":"1977","journal-title":"Arch. Int. Pharmacodyn. Ther."},{"key":"10.1016\/j.euroneuro.2013.11.009_bib40","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1016\/j.pnpbp.2005.03.004","article-title":"(+)-MK-801 induced social withdrawal in rats; a model for negative symptoms of schizophrenia","volume":"29","author":"Rung","year":"2005","journal-title":"Prog. Neuropsychopharmacol. Biol. Psychiatry"},{"key":"10.1016\/j.euroneuro.2013.11.009_bib41","doi-asserted-by":"crossref","first-page":"56","DOI":"10.3371\/CSRP.4.1.5","article-title":"Dopamine D2 receptors as treatment targets in schizophrenia","volume":"4","author":"Seeman","year":"2010","journal-title":"Clin. Schizophr. Relat. Psychoses"},{"key":"10.1016\/j.euroneuro.2013.11.009_bib42","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.bbr.2011.05.034","article-title":"Antipsychotic drugs reverse MK-801-induced cognitive and social interaction deficits in zebrafish (Danio rerio)","volume":"224","author":"Seibt","year":"2011","journal-title":"Behav. Brain Res."},{"key":"10.1016\/j.euroneuro.2013.11.009_bib43","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1016\/j.bbr.2009.02.007","article-title":"Evaluation of NMDA receptor models of schizophrenia: divergences in the behavioral effects of sub-chronic PCP and MK-801","volume":"204","author":"Seillier","year":"2009","journal-title":"Behav. Brain Res."},{"key":"10.1016\/j.euroneuro.2013.11.009_bib44","doi-asserted-by":"crossref","first-page":"859","DOI":"10.2165\/11586650-000000000-00000","article-title":"Meta-analysis of the efficacy of adjunctive NMDA receptor modulators in chronic schizophrenia","volume":"25","author":"Singh","year":"2011","journal-title":"CNS Drugs"},{"key":"10.1016\/j.euroneuro.2013.11.009_bib45","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1007\/s12031-010-9447-5","article-title":"Phencyclidine (PCP)-induced disruption in cognitive performance is gender-specific and associated with a reduction in brain-derived neurotrophic factor (BDNF) in specific regions of the female rat brain","volume":"43","author":"Snigdha","year":"2011","journal-title":"J. Mol. Neurosci."},{"key":"10.1016\/j.euroneuro.2013.11.009_bib46","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1001\/jamapsychiatry.2013.1195","article-title":"Support for the N-methyl-d-aspartate receptor hypofunction hypothesis of schizophrenia from exome sequencing in multiplex families","volume":"70","author":"Timms","year":"2013","journal-title":"JAMA Psychiatry"},{"key":"10.1016\/j.euroneuro.2013.11.009_bib47","unstructured":"Umbricht, D., Yoo, K., Youssef, E., Dorflinger, E., Martin-Facklam, M., Bausch, A., Arrowsmith, R., Alberati, D., Marder, S.R., Santarelli, L., 2010. Glycine transporter type 1 (GLYT1) inhibitor RG1678: Positive results of the proof-of-concept study for the treatment of negative symptoms in schizophrenia. In: Conference Proceeding of the 49th Annual Meeting, ACNP, Miami Beach, FL. Neuropsychopharmacology, vol. 35, pp. S320\u2013S321."},{"key":"10.1016\/j.euroneuro.2013.11.009_bib48","doi-asserted-by":"crossref","first-page":"3512","DOI":"10.1152\/jn.00018.2006","article-title":"Presynaptic plasticity in an immature neocortical network requires NMDA receptor activation and BDNF release","volume":"96","author":"Walz","year":"2006","journal-title":"J. Neurophysiol."},{"key":"10.1016\/j.euroneuro.2013.11.009_bib49","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1002\/jnr.20559","article-title":"Differential effects of acute and subchronic administration on phencyclidine-induced neurodegeneration in the perinatal rat","volume":"81","author":"Wang","year":"2005","journal-title":"J. Neurosci. Res."},{"key":"10.1016\/j.euroneuro.2013.11.009_bib50","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1007\/BF00508778","article-title":"Dopamine-like activities of an aminopyridazine derivative, CM 30366: a behavioural study","volume":"334","author":"Worms","year":"1986","journal-title":"Naunyn Schmiedebergs Arch. Pharmacol."},{"key":"10.1016\/j.euroneuro.2013.11.009_bib51","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1007\/978-3-7091-0932-8_22","article-title":"Synaptic dysfunction in schizophrenia","volume":"970","author":"Yin","year":"2012","journal-title":"Adv. Exp. Med. Biol."}],"container-title":["European Neuropsychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924977X13003404?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924977X13003404?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,7,9]],"date-time":"2023-07-09T02:14:07Z","timestamp":1688868847000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0924977X13003404"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,3]]},"references-count":51,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2014,3]]}},"alternative-id":["S0924977X13003404"],"URL":"https:\/\/doi.org\/10.1016\/j.euroneuro.2013.11.009","relation":{},"ISSN":["0924-977X"],"issn-type":[{"value":"0924-977X","type":"print"}],"subject":[],"published":{"date-parts":[[2014,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A novel analog of olanzapine linked to sarcosinyl moiety (PGW5) demonstrates high efficacy and good safety profile in mouse models of schizophrenia","name":"articletitle","label":"Article Title"},{"value":"European Neuropsychopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.euroneuro.2013.11.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 Elsevier B.V. and ECNP. All rights reserved.","name":"copyright","label":"Copyright"}]}}